The Industry

August 2007
Pharmaceutical Representative;Aug2007, Vol. 37 Issue 8, p10
The article reports developments related to the pharmaceutical industry in the U.S. Thousand Oaks, California-based Amgen will be acquiring the biopharmaceutical companies, Ilypsa Inc. and Alantos. Massachusetts-based Critical Therapeutics Inc. agreed to co-promote in the U.S. the drug Perforomist (formoterol fumarate) from Dey L.P. Cambridge, Massachusetts-based Genzyme Corp. signed an agreement to buy the oncology firm Bioenvision for approximately $345 million.


Related Articles

  • Amgen diversifies portfolio.  // ICIS Chemical Business Americas;7/2/2007, Vol. 272 Issue 1, p36 

    The article reports on the efforts of Amgen to diversify its portfolio through the acquisition of Alantos Pharmaceutical and Ilypsa. Report says that with both acquisitions, Amgen gets late-stage candidates that broaden its product portfolio into significant therapeutic areas. According to...

  • Amgen Offers $420M For Ilypsa, CKD Therapy.  // Bioworld Week;6/11/2007, Vol. 15 Issue 24, p3 

    The article reports on the plans of Amgen Inc. to buy Ilypsa Inc. for $240 million. Under the terms of the deal, Ilypsa would become a wholly owned subsidiary of Amgen. The merger is expected to close in the third quarter of 2007. Ilypsa's lead product, ILY101, is an oral non-absorbed polymeric...

  • Genzyme bulks up. Mirasol, Feliza // ICIS Chemical Business Americas;6/4/2007, Vol. 271 Issue 22, p40 

    The article reports that Genzyme has signed an agreement to acquire Bioenvision, a company that focuses on the acquisition, development and marketing of cancer treatments. The deal will be an all-cash transaction valued at roughly $345 million, or $5.60/outstanding common share. The two...

  • Genzyme/Bioenvision: maximizing gains through acquisition.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p17 

    The article reports on the acquisition of Bioenvision Inc. by Genzyme Corp. Gaining full marketing rights for the drug triggered Genzyme's decision to acquire the New York-based biotechnology. In addition to gaining full marketing rights to Clolar drug, Genzyme will obtain Modrenal drug which is...

  • Bioenvision shareholders approve acquisition by Genzyme.  // PharmaWatch: Biotechnology;Dec2007, Vol. 6 Issue 12, p17 

    The article reports that the stockholders of biopharmaceutical company Bioenvision Inc. have voted to approve the acquisition of the company by Genzyme Corp. in an all cash transaction valued at $5.60 per share in the U.S. According to the report, the acquisition will give Genzyme control over...

  • Genzyme Buys Clofarabine Partner In $345M Deal.  // Bioworld Week;6/4/2007, Vol. 15 Issue 23, p1 

    The article reports on the move of Genzyme Corp. of Cambridge, Massachusetts to acquire partner Bioenvision Inc. of New York in a deal worth approximately $345 million. Genzyme plans to expand clofarabine's label from pediatric acute lymphoblastic leukemia (ALL) to adult acute myeloid leukemia....

  • CORPORATE.  // MondayMorning;11/22/2010, Vol. 18 Issue 43, p2 

    The article offers news briefs related to drug industry in the U.S. Cardinal Health Inc. has planned to acquire Kinray Inc. worth 1.3 billion dollars. Takeda Pharmaceutical Co. Ltd. will takeover Genzyme Corp. Amgen Inc. has got approval for its osteoporosis drug called Denosumab for reducing...

  • Amgen's Ilypsa Buy: $420M Gets Phase II CKD Therapy. Osborne, Randall // BioWorld Today;6/6/2007, Vol. 18 Issue 109, p1 

    The article reports on the plan of Amgen Inc. to buy out nephrology-focused Ilypsa Inc. for $429 million in which Amgen will gain a Phase II phosphate binder for chronic kidney disease (CKD). According to Robbert van Batenburg, head of research for Louis Capital Markets, the takeover is an...

  • Enzyme Buyout: 'Low Ball' Price Offered For Bio envision. Osborne, Randall // BioWorld Financial Watch;6/4/2007, Vol. 15 Issue 23, p1 

    The article reports on the plans of Genzyme Corp. to buy clofarabine partner Bioenvision Inc. for about $345 million in cash in July 2007. On May 29, 2007, news has broken out that Genzyme would pay $5.60 per outstanding share of envision, a 50 percent premium over the average share price during...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics